Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Entacapone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT known ✓ | P21964 | 5/20 | 1.00 |
| ▸ | FTO | Q9C0B1 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Entacapone SCHEMBL3395296 | 1.00 | FTO (1.00) | FTOCOMTMEN1KMT2AABCC3 | |
| Entacapone SCHEMBL34505 | 1.00 | FTO (1.00) | FTOCOMTMEN1KMT2AABCC3 | |
| Entacapone SCHEMBL34504 | 1.00 | FTO (1.00) | FTOCOMTMEN1KMT2AABCC3 | |
| Entacapone SCHEMBL3934631 | 1.00 | FTO (1.00) | FTOCOMTMEN1KMT2AABCC3 | |
| Entacapone SCHEMBL29406523 | 1.00 | FTO (1.00) | FTOCOMTMEN1KMT2AABCC3 | |
| Entacapone SCHEMBL27766815 | 0.99 | FTO (0.98) | FTOCOMTMEN1KMT2AABCC3 | |
| Entacapone SCHEMBL4940150 | 0.98 | FTO (0.96) | FTOCOMTMEN1KMT2AABCC3 | |
| Entacapone SCHEMBL4940155 | 0.98 | FTO (0.96) | FTOCOMTMEN1KMT2AABCC3 | |
| Entacapone SCHEMBL26128138 | 0.97 | FTO (0.94) | FTOCOMTMEN1KMT2AABCC3 | |
| Entacapone SCHEMBL3972337 | 0.96 | FTO (0.92) | FTOCOMTMEN1KMT2AABCC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | APTARGROUP, INC. (US) | 2026-04-07 | — | — | US | claimed |
| EP-3768263-B1 | CONTINUOUS ADMINISTRATION OF PHARMACEUTICAL COMPOSITION FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | LOBSOR PHARMACEUTICALS AB (SE) | 2025-10-29 | — | — | EP | claimed |
| US-20250235641-A1 | DEVICE TO DELIVER A PREDETERMINED AMOUNT OF A SUBSTANCE TO A NATURAL ORIFICE OF THE BODY | APTARGROUP INC. (US) | 2025-07-24 | — | — | US | claimed |
| EP-3638673-B9 | TETRAHYDROPYRIDOPYRAZINE MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-20 | — | — | EP | claimed |
| EP-4284387-B1 | NAD-AUGMENTATION THERAPY FOR PARKINSON'S DISEASE | VESTLANDETS INNOVASJONSSELSKAP AS VIS (NO) | 2024-07-31 | — | — | EP | claimed |
| EP-3638673-B1 | TETRAHYDROPYRIDOPYRAZINE MODULATORS OF GPR6 | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-17 | — | — | EP | claimed |
| EP-2713883-B1 | METHODS FOR PREVENTING AND TREATING MOTOR-RELATED NEUROLOGICAL CONDITIONS | CLARENCEW PTY LTD (AU) | 2024-07-10 | — | — | EP | claimed |
| EP-3897641-B1 | TREATMENT OF MOVEMENT DISORDERS | CONTERA PHARMA AS (DK) | 2023-11-15 | — | — | EP | claimed |
| US-20230116253-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-04-13 | — | — | US | claimed |
| US-20220409830-A1 | DEVICE TO DELIVER A PREDETERMINED AMOUNT OF A SUBSTANCE TO A NATURAL ORIFICE OF THE BODY | SIPNOSE LTD. (IL) | 2022-12-29 | — | — | US | claimed |
| EP-3237399-B1 | COMPOUNDS, COMPOSITIONS AND METHODS | AVALO THERAPEUTICS INC (US) | 2022-11-30 | — | — | EP | claimed |
| CN-108440340-B | Method for preparing entacapone | 北京伊斯康科技有限公司 | 2022-08-26 | — | — | CN | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3503883-B1 | ENTACAPONE-RELATED COMPOUNDS TO TREAT MACULAR DEGENERATION | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2022-05-04 | — | — | EP | claimed |
| EP-3782614-B1 | MUCO-ADHESIVE, CONTROLLED RELEASE FORMULATIONS OF LEVODOPA AND/OR ESTERS OF LEVODOPA AND USES THEREOF | IMPAX LABORATORIES LLC (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | ALTO NEUROSCIENCE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| CN-114099686-A | Bone marrow derived suppressor cell suppression and immune checkpoint blockade | 约翰·霍普金斯大学 | 2022-03-01 | — | — | CN | disclosed |
| EP-3955918-A1 | METHODS OF TREATING NEUROCOGNITIVE DISORDERS, CHRONIC PAIN AND REDUCING INFLAMMATION | COMPASS Pathfinder Limited (GB) | 2022-02-23 | — | — | EP | disclosed |
| EP-3943157-A1 | AGENT FOR TREATING PARKINSON'S DISEASE | Kyowa Kirin Co., Ltd. (JP) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116253-A1 | DIACYLGLYERCOL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | COMT 2930/4885FTO 3752/4885MEN1 3337/4885 |
| US-12594388-B2 | Device to deliver a predetermined amount of a substance to a natural orifice of the body | TNF, PYCARD, VAPA | COMT 2843/4885FTO 3322/4885MEN1 3247/4885 |
| US-12622895-B2 | Anti-neurodegenerative combinations and use for treatment of neurodegenerative diseases | HTR1D, PARK7, HTR3A | COMT 183/4885FTO 2971/4885MEN1 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.